Zealand Pharma Announces First Participant Enrolled in ZUPREME-1 Phase 2b Trial

Zealand Pharma (ZLDPF) has announced the enrollment of the first participant in the ZUPREME-1 trial, a global Phase 2b study. This trial aims to evaluate the efficacy, safety, and tolerability of petrelintide, a long-acting amylin analog, administered subcutaneously once a week, compared to a placebo. The study targets individuals suffering from obesity or overweight with weight-related co-morbidities.

David Kendall, MD, Chief Medical Officer at Zealand Pharma, highlighted the significance of this milestone, stating, "The initiation of this large and comprehensive Phase 2b trial of petrelintide in people with overweight or obesity marks an important milestone for Zealand." He further expressed optimism about petrelintide's potential as a best-in-class alternative to incretin-based therapies and its future role in weight management.

Looking ahead, Zealand Pharma plans to expand the development program for petrelintide, with the initiation of a Phase 2b trial in individuals with overweight or obesity and type 2 diabetes scheduled for the first half of 2025.